Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: J Immunol. 2009 Mar 1;182(5):2726–2737. doi: 10.4049/jimmunol.0803479

Figure 2.

Figure 2

Characterization of tumor infiltrating DC (TIDC). Skin DLN and dermal DC, as well as B16.F10 TIDC (CD3−CD19−CD11c+I-Ab+) were analyzed for expression of EpCAM, PDCA-1, CD8α and CD4 in a series of progressive gating plots (A). Numbers in the plots indicate percent cells in respective gate. Skin DLN, B16.F10 DLN, 1×2cm2 patch of skin, and day-12 B16.F10 tumors were harvested and analyzed for the total number of CD11b+ DC (B), and their approximate tissue density (C). B16.F10 frozen tissue sections were examined for CD11c, I-Ab and DAPI staining (left), and for co-localization of CD11c, I-Ab, and CD11b (zoomed-in and merge insets, right) (D). Expression of I-Ab vs. CD86, CD80 and CD40 was examined on CD11b+ LN DC and TIDC (E). Numbers in the plots indicate MFI of the analyzed marker for either the I-Ab+bright (top) or I-Ab+dim (bottom) population. Data are representative of at least two independent experiments.